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Voriconazole pharmacokinetics shows a large inter- and intrapatient variability. Inflammation is associated with changes in the
expression of CYP isoenzymes. Here, we evaluated the influence of inflammation, marked by C-reactive protein (CRP) levels in
blood, on the metabolism of voriconazole. Observational data showed an association between CRP level and the ratio of
voriconazoleN-oxide to voriconazole.
Voriconazole (VCZ) is recommended as a first-line treatmentfor invasive aspergillosis (1). It undergoes extensive hepatic
metabolism, primarily by CYP2C19 and to a lesser extent by
CYP3A4 and CYP2C9. Besides polymorphism as a predominant
factor generating highly variable interpatient pharmacokinetics of
VCZ, drug-drug interactions and liver function may also influ-
ence VCZ exposure (2–4). A recent observation of high VCZ con-
centrations during severe inflammation (5) could explain a part of
the previously observed large intrapatient variability (6). This ef-
fect was explained by a downregulation of drug-metabolizing en-
zymes caused by inflammation (7, 8).
To further elucidate this clinical observation, it was relevant to
evaluate the metabolic rate of VCZ during periods of severe in-
flammation. Themetabolic rate of VCZwas expressed as the ratio
ofN-oxide VCZ to VCZ (metabolic ratio [MR]). In this study, we
hypothesize that theN-oxide VCZ/VCZ ratio would be decreased
during severe inflammation (defined by C-reactive protein [CRP]
levels of100mg/ml), possibly due to a decrease in themetabolic
function of CYP2C19.
In this study, performed in the University Medical Centre
Groningen, the Netherlands, medical data from patients who
received intravenous or oral VCZ for treatment or prophylaxis
between December 2012 and July 2013 and were subjected to
therapeutic-drug monitoring (TDM) and monitoring of CRP
were retrospectively analyzed. All patients aged at least 18 years
who received VCZ were considered eligible for the study if they
had at least 3 data sets of N-oxide VCZ/VCZ concentration
ratios and corresponding CRP levels determined on the same
day. This study, being of a retrospective nature, was evaluated
by the local ethics committee (IRB 2013-491) and was ap-
proved according to Dutch law.
Patients were excluded if a strong cytochrome P450 inducer or
inhibitor affecting VCZ metabolism was coadministered (4) or if
the mean value of liver function tests exceeded 5 times the upper
level of normal. The liver functions evaluated were alanine ami-
notransferase (ALT; normal value,45U/liter), aspartate amino-
transferase (AST; normal value, 40 U/liter), alkaline phospha-
tase (AP; normal value, 120 U/liter), and bilirubin (normal
value, 5.1 to 32.5 mol/liter). VCZ and N-oxide VCZ concentra-
tions were measured with a validated and verified assay (9, 10).
CRP was measured by a turbidimetric assay (Roche Modular;
Roche, Mannheim, Germany).
In the study, data for a total of 77 patients who were subjected
to routine TDM during the period from December 2012 to July
2013were evaluated. After the evaluation, 28 patients were eligible
for the study because of having a complete data set of VCZ levels
and CRP concentration in blood samples taken together on the
same day. From this group, 9 patients were excluded because of
drug-drug interaction (DDI) (n 6) and liver dysfunction (n
3), and thus, 19 patients remained in the study. The demographic
information and descriptive statistics of the selected patients are
summarized in Table 1. In total, 101 data sets were available for
analysis, ranging from 3 to 21 data sets per patient. The mean
metabolic ratio was 2.4, with a 95% confidence interval (CI) of 0.0
to 30.0. The mean plasma concentration of CRP was 76.6 (range,
5.0 to 279.0), that of VCZwas 3.4mg/liter (range, 0.1 to 12.3), and
that of N-oxide VCZ was 2.4 mg/liter (range, 0.1 to 8.4).
The association between the MR and CRP levels from all se-
lected patients was analyzed using correlation analysis. Our data
confirm that an inflammatory response is significantly positively
associated with the VCZ concentration (rho 0.62; 95% CI, 0.48
to 0.73; P  0.001) and negatively associated with the metabolic
ratio (rho0.64; 95% CI,0.77 to0.50; P 0.001). A com-
parison of the Pearson (parametric) and Spearman (nonparamet-
ric) coefficients of correlation was used to show the normal distri-
bution of the data. An important limitation of the study is that
infrequent sampling for VCZ and CRP in routine care made it
difficult to detect subtle changes in metabolic clearance. Differ-
ences in response rates to antimicrobial treatment affecting in-
flammation complicated the alignment of the results with respect
to time for mixed effects modeling. A linear mixedmodel analysis
(with a random intercept for subjects) was performed to assess the
influence of inflammation on the variability in VCZ trough con-
centrations and MR. VCZ increased with 0.021 mg/liter for unit
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increase in the CRP level, and MR decreased with a 0.010 for
every unit increase in the CRP level (P  0.001 for both results).
Liver function tests showed no significant influence on eitherVCZ
orMR. The hypothesis that metabolism of VCZ is reduced during
severe inflammation seems plausible, as shown by the significant
negative correlation between CRP and the MR. It should be kept
in mind that in this study, the heterogeneous population was rel-
atively small due to a lack of available data from routine care.
Despite this limitation, inflammation seems to be a relevant
source of VCZ pharmacokinetic variability (5), because otherma-
jor factors, such as DDI and hepatic dysfunction, were a reason to
exclude patients. If information onCYP2C19 polymorphisms had
been available, it is likely that the pharmacokinetic variability
could have been explained even better (11). Due to this lack of
information on genetic polymorphism in our study, the difference
in the extent of the effect of inflammation on the VCZ concentra-
tions between patients who are poor metabolizers or extensive
metabolizers remains to be evaluated. It can be speculated that, in
cases of poor metabolism, a dose reduction during inflammation
is warranted to avoid toxicity.
Nevertheless, prospective studies with frequent sampling are
needed to investigate the true impact of this phenomenon. This
could be important not only for VCZ but also for other drugs that
are metabolized by CYP2C19. Depending on the therapeutic win-
dows of these drugs, patients may experience side effects during
severe inflammation, due to decreased metabolism resulting in
high drug plasma concentrations.
The findings in our study are consistent with and confirm the
ideas of Morgan and collaborators, who claimed that CYP450-
mediated drugmetabolism is reducedduring severe inflammation
(7, 8). Therefore, consideration of the effects of an inflammatory
state on the variability in drug response should be an integral part
of a personalized treatment. For instance, routine TDMof VCZ in
the clinic has been suggested to reduce the number of discontinu-
ations of VCZ treatment due to adverse events and even to im-
prove the success rate in the treatment of invasive fungal infec-
tions (12).
In conclusion, this study provides support for the hypothesis
that the effect of an inflammatory response onVCZmetabolism is
a source of the variability of VCZplasma concentrations. Our data
show that inflammation and infection play a role in the largely
unpredictable pharmacokinetics of VCZ. As a consequence, phy-
sicians should be aware of this phenomenon in order to avoid
inflammation-associated increasing levels of VCZ and, thereby,
toxic responses to VCZ.
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TABLE 1 Demographic and clinical characteristics of patients
Parameter Resulta (n 19 patients)
Characteristics
Female/male 6/13
Age (yr) 57 (IQR, 18–68)
Wt (kg) 63 (IQR, 50–92)







Transition from i.v. to oral/oral to i.v. (%) 26/5
Dose (mg twice a day) 200 (R, 150–320)
Laboratory findings
CRP (mg/liter) 76.6 (R, 5.0–279.0)
VCZ (mg/liter) 3.3 (R, 0.1–12.3)
N-oxide VCZ (mg/liter) 2.4 (R, 0.1–8.4)
ALT (U/liter) 93.70 (IQR, 11–107.7)
AST (U/liter) 51.07 (IQR, 8–409)
Alkaline phosphatase (U/liter) 130 (IQR, 47–258)
Total bilirubin (mol/liter) 9 (IQR, 6–16)
a Values are the number, percent, mean (range [R]), or median (interquartile range
[IQR]), as indicated.
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